Table 4 Clinical and laboratory characteristics in death group and survival group
Clinical and laboratory parameters | Death group (n = 4) | Survival group (n = 18) | P |
|---|---|---|---|
Age | 56.8 ± 12.5 | 58.4 ± 9.3 | 0.760 |
Sex | 0.671 | ||
Male (%) | 5 (71.4) | 9 (60) | |
Female (%) | 2 (28.6) | 6 (40) | |
Drug duration (days) | 15.0 ± 6.5 | 13.7 ± 9.4 | 0.792 |
Drug total dose (mg) | 4500 ± 1944 | 3977.8 ± 2759.7 | 0.726 |
WBC (× 103/uL) | 9.0 ± 7.1 | 6.6 ± 2.7 | 0.254 |
CK (U/L) | 27,111.3 ± 29,658.8 | 19,769.7 ± 12,078.8 | 0.416 |
LDH (U/L) | 3681.5 ± 3142.2 | 2018.2 ± 710.6 | 0.042 |
AST (U/L) | 1495.8 ± 718.3 | 967.3 ± 553.9 | 0.622 |
ALT (U/L) | 420.3 ± 263.7 | 374.6 ± 235.1 | 0.736 |
Albumin (g/dL) | 2.8 ± 0.3 | 2.8 ± 0.7 | 0.957 |
BUN (mg/dL) | 64.7 ± 22.5 | 22.0 ± 20.1 | 0.001 |
Creatinine (mg/dL) | 4.5 ± 1.9 | 1.3 ± 1.7 | 0.003 |
Sodium (mmol/L) | 126.9 ± 3.8 | 137.6 ± 5.2 | 0.001 |
Potassium (mmol/L) | 5.3 ± 0.9 | 4.4 ± 0.5 | 0.019 |
Hospital days | 21.8 ± 11.6 | 21.1 ± 9.6 | 0.908 |
Clinical signs and symptoms | |||
Muscle pain (%) | 7 (100) | 13 (86.7) | 1.000 |
Muscle weakness (%) | 3 (42.9) | 6 (40.0) | 0.616 |
Oliguria (%) | 4 (57.1) | 0 (0) | 0.135 |
Dark urine (%) | 2 (28.6) | 1 (6.7) | 1.000 |
LC (%) | 4 (100) | 15 (83.3) | 1.000 |
Child-Pugh classification | 0.312 | ||
A (%) | 0 (0) | 3 (20.0) | |
B (%) | 0 (0) | 7 (46.7) | |
C (%) | 4 (100) | 5 (33.3) | |
Severe hepatic derangement | 4 (100) | 5 (33.3) | 0.017 |
Etiology of LC | 1.000 | ||
Hepatitis B (%) | 3 (75) | 9 (60) | |
Hepatitis C (%) | 0 (0) | 2 (13.3) | |
Alcohol (%) | 1 (25) | 3 (20) | |
Cryptogenic (%) | 0 (0) | 1 (6,7) | |
ARF (%) | 4 (100) | 3 (16.7) | 0.005 |